Last reviewed · How we verify
lopinavir/ritonavir soft gel capsule
lopinavir/ritonavir soft gel capsule is a Protease inhibitor Small molecule drug developed by Bamrasnaradura Infectious Diseases Institute. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children. Also known as: Kaletra.
Lopinavir/ritonavir is a combination of two antiretroviral drugs that inhibit the protease enzyme in HIV, preventing viral replication.
Lopinavir/ritonavir is a combination of two antiretroviral drugs that inhibit the protease enzyme in HIV, preventing viral replication. Used for Treatment of HIV-1 infection in adults and children.
At a glance
| Generic name | lopinavir/ritonavir soft gel capsule |
|---|---|
| Also known as | Kaletra |
| Sponsor | Bamrasnaradura Infectious Diseases Institute |
| Drug class | Protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Lopinavir is a protease inhibitor that binds to the protease enzyme, preventing it from cleaving viral proteins. Ritonavir is a protease inhibitor that also inhibits the CYP3A4 enzyme, increasing the levels of lopinavir in the body.
Approved indications
- Treatment of HIV-1 infection in adults and children
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors (NA)
- Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection (NA)
- Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects (PHASE3)
- Ritonavir-boosted Lopinavir Monotherapy (PHASE3)
- A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lopinavir/ritonavir soft gel capsule CI brief — competitive landscape report
- lopinavir/ritonavir soft gel capsule updates RSS · CI watch RSS
- Bamrasnaradura Infectious Diseases Institute portfolio CI
Frequently asked questions about lopinavir/ritonavir soft gel capsule
What is lopinavir/ritonavir soft gel capsule?
How does lopinavir/ritonavir soft gel capsule work?
What is lopinavir/ritonavir soft gel capsule used for?
Who makes lopinavir/ritonavir soft gel capsule?
Is lopinavir/ritonavir soft gel capsule also known as anything else?
What drug class is lopinavir/ritonavir soft gel capsule in?
What development phase is lopinavir/ritonavir soft gel capsule in?
What are the side effects of lopinavir/ritonavir soft gel capsule?
What does lopinavir/ritonavir soft gel capsule target?
Related
- Drug class: All Protease inhibitor drugs
- Target: All drugs targeting HIV protease
- Manufacturer: Bamrasnaradura Infectious Diseases Institute — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of HIV-1 infection in adults and children
- Also known as: Kaletra
- Compare: lopinavir/ritonavir soft gel capsule vs similar drugs
- Pricing: lopinavir/ritonavir soft gel capsule cost, discount & access